{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T15:39:41Z","timestamp":1795016381028,"version":"4.10.1"},"reference-count":329,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"am","delay-in-days":322,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.neuropharm.2023.109422","type":"journal-article","created":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T11:47:17Z","timestamp":1673610437000},"page":"109422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"special_numbering":"C","title":["Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment"],"prefix":"10.1016","volume":"226","author":[{"given":"Jenessa N.","family":"Johnston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashkim","family":"Kadriu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica R.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioline D.","family":"Henter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Carlos A.","family":"Zarate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2023.109422_bib1","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/da.22501","article-title":"Ketamine's mechanism of action: a path to rapid\u2010acting antidepressants","volume":"33","author":"Abdallah","year":"2016","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.neuropharm.2023.109422_bib2","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/npp.2016.186","article-title":"Ketamine treatment and global brain connectivity in major depression","volume":"42","author":"Abdallah","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib3","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s41386-020-0644-9","article-title":"Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin","volume":"45","author":"Abdallah","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib4","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1038\/npp.2017.49","article-title":"The nucleus accumbens and ketamine treatment in major depressive disorder","volume":"42","author":"Abdallah","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib5","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1007\/s12035-021-02718-x","article-title":"Combination of electroconvulsive stimulation with ketamine or escitalopram protects the brain against inflammation and oxidative stress induced by maternal deprivation and is critical for associated behaviors in male and female rats","volume":"59","author":"Abelaira","year":"2022","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib6","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jpsychires.2020.06.012","article-title":"Can \u2018floating\u2019predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression","volume":"130","author":"Acevedo-Diaz","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2023.109422_bib8","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jad.2019.11.028","article-title":"Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression","volume":"263","author":"Acevedo-Diaz","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2023.109422_bib9","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1021\/acsptsci.1c00014","article-title":"Predicting reactions to psychedelic drugs: a systematic review of states and traits related to acute drug effects","volume":"4","author":"Aday","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib10","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00213-022-06123-7","article-title":"Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials","volume":"239","author":"Aday","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2023.109422_bib11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/0269881119897615","article-title":"Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer","volume":"34","author":"Agin-Liebes","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib12","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/ijnp\/pyz041","article-title":"(R)-ketamine induces a greater increase in prefrontal 5-HT release than (S)-ketamine and ketamine metabolites via an AMPA receptor-independent mechanism","volume":"22","author":"Ago","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib13","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41586-020-03047-0","article-title":"Antidepressant actions of ketamine engage cell-specific translation via eIF4E","volume":"590","author":"Aguilar-Valles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2023.109422_bib14","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.tips.2021.08.003","article-title":"Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics","volume":"42","author":"Aleksandrova","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib15","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jpsychires.2018.02.011","article-title":"Kynurenine pathway metabolism and the neurobiology of treatment-resistant depression: comparison of multiple ketamine infusions and electroconvulsive therapy","volume":"100","author":"Allen","year":"2018","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2023.109422_bib16","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jpsychires.2022.04.037","article-title":"Real-world effectiveness of ketamine in treatment-resistant depression: a systematic review & meta-analysis","volume":"151","author":"Alnefeesi","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2023.109422_bib17","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.bcp.2005.12.022","article-title":"A role for AMPA receptors in mood disorders","volume":"71","author":"Alt","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib18","doi-asserted-by":"crossref","first-page":"844","DOI":"10.3389\/fpsyt.2020.00844","article-title":"The antidepressant effect of ketamine is dampened by concomitant benzodiazepine medication","volume":"11","author":"Andrashko","year":"2020","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/PL00000199","article-title":"Differential anti-inflammatory effects of immunosuppressive drugs: cyclosporin, rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and PGE2 production","volume":"49","author":"Attur","year":"2000","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.neuropharm.2023.109422_bib21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2023.109422_bib22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jad.2022.01.104","article-title":"mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression","volume":"303","author":"Averill","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2023.109422_bib23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jad.2017.04.057","article-title":"Anhedonia as a clinical correlate of suicidal thoughts in clinical ketamine trials","volume":"218","author":"Ballard","year":"2017","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2023.109422_bib24","doi-asserted-by":"crossref","first-page":"6431","DOI":"10.1038\/s41467-020-20190-4","article-title":"The role of dissociation in ketamine's antidepressant effects","volume":"11","author":"Ballard","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2023.109422_bib25","series-title":"Behavioral Neurobiology of Psychedelic Drugs","first-page":"393","article-title":"Classic hallucinogens and mystical experiences: phenomenology and neural correlates","author":"Barrett","year":"2018"},{"key":"10.1016\/j.neuropharm.2023.109422_bib26","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.4693","article-title":"Association of ketamine with psychiatric symptoms and implications for its therapeutic use and for understanding schizophrenia: a systematic review and meta-analysis","volume":"3","author":"Beck","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.neuropharm.2023.109422_bib27","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3389\/fphar.2018.00208","article-title":"Metabotropic glutamate2 receptors play a key role in modulating head twitches induced by a serotonergic hallucinogen in mice","volume":"9","author":"Benvenga","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib28","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0896-6273(00)81056-9","article-title":"Addiction, dopamine, and the molecular mechanisms of memory","volume":"25","author":"Berke","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2023.109422_bib29","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.encep.2020.12.002","article-title":"[Efficacy of psychedelics in psychiatry, a systematic review of the literature] [French]","volume":"47","author":"Berkovitch","year":"2021","journal-title":"Encephale"},{"key":"10.1016\/j.neuropharm.2023.109422_bib30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/ALN.0000000000001704","article-title":"Ketamine and etomidate down-regulate the hypothalamic-pituitary-adrenal axis in an endotoxemic mouse model","volume":"127","author":"Besnier","year":"2017","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib31","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1007\/s00213-014-3557-7","article-title":"Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes","volume":"231","author":"Blough","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib32","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1038\/s41380-021-01093-2","article-title":"Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability","volume":"26","author":"Bonaventura","year":"2021","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bbi.2022.05.015","article-title":"Exaggerated amygdala response to threat and association with immune hyperactivity in depression","volume":"104","author":"Boukezzi","year":"2022","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2023.109422_bib34","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.biopsych.2015.04.022","article-title":"Ketamine as a prophylactic against stress-induced depressive-like behavior","volume":"79","author":"Brachman","year":"2016","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib35","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.psyneuen.2010.08.011","article-title":"The double edged sword of neural plasticity: increasing serotonin levels leads to both greater vulnerability to depression and improved capacity to recover","volume":"36","author":"Branchi","year":"2011","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib36","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-neuro-062111-150444","article-title":"Mechanisms of gamma oscillations","volume":"35","author":"Buzs\u00e1ki","year":"2012","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib37","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jpsychires.2021.09.057","article-title":"The resilient phenotype elicited by ketamine against inflammatory stressors-induced depressive-like behavior is associated with NLRP3-driven signaling pathway","volume":"144","author":"Camargo","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2023.109422_bib38","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","article-title":"A non-hallucinogenic psychedelic analogue with therapeutic potential","volume":"589","author":"Cameron","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2023.109422_bib39","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.abl8615","article-title":"Structure-based discovery of nonhallucinogenic psychedelic analogs","volume":"375","author":"Cao","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2023.109422_bib40","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1177\/0269881116662634","article-title":"Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences","volume":"30","author":"Carbonaro","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib41","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2023.109422_bib42","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib43","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib44","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Carhart-Harris","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2023.109422_bib45","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/npp.2017.84","article-title":"The therapeutic potential of psychedelic drugs: past, present, and future","volume":"42","author":"Carhart-Harris","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib46","doi-asserted-by":"crossref","first-page":"4853","DOI":"10.1073\/pnas.1518377113","article-title":"Neural correlates of the LSD experience revealed by multimodal neuroimaging","volume":"113","author":"Carhart-Harris","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2023.109422_bib47","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/0269881117725915","article-title":"Serotonin and brain function: a tale of two receptors","volume":"31","author":"Carhart-Harris","year":"2017","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib48","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13282-7","article-title":"Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms","volume":"7","author":"Carhart-Harris","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2023.109422_bib49","series-title":"New Rapid-Acting Antidepressants","first-page":"111","article-title":"mGlu2\/3 receptor antagonists as rapid-acting antidepressants","author":"Chaki","year":"2021"},{"key":"10.1016\/j.neuropharm.2023.109422_bib50","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.3390\/ijms20061270","article-title":"Role of serotonergic system in the antidepressant actions of mGlu2\/3 receptor antagonists: similarity to ketamine","volume":"20","author":"Chaki","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1192\/bjp.2018.66","article-title":"Treatment-resistant depression and peripheral C-reactive protein","volume":"214","author":"Chamberlain","year":"2019","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109422_bib52","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00406-019-01012-1","article-title":"Lack of dopamine D1 receptors in the antidepressant actions of (R)-ketamine in a chronic social defeat stress model","volume":"270","author":"Chang","year":"2020","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib53","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/j.jss.2012.02.023","article-title":"Multifaceted effects of rapamycin on functional recovery after spinal cord injury in rats through autophagy promotion, anti-inflammation, and neuroprotection","volume":"179","author":"Chen","year":"2013","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.neuropharm.2023.109422_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/IJTR.S2097","article-title":"Kynurenine pathway metabolites in humans: disease and healthy states","volume":"2","author":"Chen","year":"2009","journal-title":"Int. J. Tryptophan Res."},{"issue":"9","key":"10.1016\/j.neuropharm.2023.109422_bib55","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1016\/j.biopsych.2022.02.546","article-title":"P310. Effect of a sub-anesthetic infusion of ketamine on laboratory-induced stress in healthy volunteers: a proof-of-concept translational study","volume":"91","author":"Costi","year":"2022","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib56","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12888-022-03789-3","article-title":"Neurocognitive effects of repeated ketamine infusion treatments in patients with treatment resistant depression: a retrospective chart review","volume":"22","author":"Dai","year":"2022","journal-title":"BMC Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib57","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1177\/0269881118769063","article-title":"The epidemiology of 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) use: benefits, consequences, patterns of use, subjective effects, and reasons for consumption","volume":"32","author":"Davis","year":"2018","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib58","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41591-022-01744-z","article-title":"Increased global integration in the brain after psilocybin therapy for depression","volume":"28","author":"Daws","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2023.109422_bib59","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1471-4159.2007.04768.x","article-title":"Quantitative analysis of glutamatergic and GABAergic neurons expressing 5-HT2A receptors in human and monkey prefrontal cortex","volume":"103","author":"De Almeida","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2023.109422_bib60","series-title":"Progress in Brain Research","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/bs.pbr.2018.07.008","article-title":"d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: mechanism of action and potential therapeutic applications in mood disorders","author":"De Gregorio","year":"2018"},{"key":"10.1016\/j.neuropharm.2023.109422_bib61","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.phrs.2016.08.022","article-title":"The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors","volume":"113","author":"De Gregorio","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2023.109422_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110507","article-title":"Electrophysiological correlates and predictors of the antidepressant response to repeated ketamine infusions in treatment-resistant depression","volume":"115","author":"de la Salle","year":"2022","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109422_bib63","first-page":"7","article-title":"Depression: the case for a monoamine deficiency","volume":"61","author":"Delgado","year":"2000","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib64","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/j.neuropharm.2012.01.010","article-title":"Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular signaling cascades","volume":"62","author":"Delille","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib65","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","article-title":"A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression","volume":"67","author":"Diazgranados","year":"2010","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib66","doi-asserted-by":"crossref","first-page":"pyv072","DOI":"10.1093\/ijnp\/pyv072","article-title":"Pharmacokinetics and concentration-effect relationship of oral LSD in humans","volume":"19","author":"Dolder","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib67","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/j.cell.2021.03.043","article-title":"Psychedelic-inspired drug discovery using an engineered biosensor","volume":"184","author":"Dong","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2023.109422_bib68","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.psyneuen.2018.05.019","article-title":"Altered tryptophan catabolite concentrations in major depressive disorder and associated changes in hippocampal subfield volumes","volume":"95","author":"Doolin","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib69","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1113\/jphysiol.2006.124958","article-title":"Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block","volume":"581","author":"Dravid","year":"2007","journal-title":"J. Physiol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib70","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/jcpt.12238","article-title":"Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression","volume":"40","author":"Drewiany","year":"2015","journal-title":"J. Clin. Pharm. Therapeut."},{"key":"10.1016\/j.neuropharm.2023.109422_bib71","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3389\/fphar.2017.00978","article-title":"S-ketamine mediates its acute and sustained antidepressant-like activity through a 5-HT1B receptor dependent mechanism in a genetic rat model of depression","volume":"8","author":"du Jardin","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib72","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/cercor\/bhab202","article-title":"Psilocybin induces aberrant prediction error processing of tactile mismatch responses\u2014a simultaneous EEG\u2013FMRI study","volume":"32","author":"Duerler","year":"2021","journal-title":"Cerebr. Cortex"},{"key":"10.1016\/j.neuropharm.2023.109422_bib73","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neuron.2019.03.013","article-title":"Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments","volume":"102","author":"Duman","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2023.109422_bib74","article-title":"Sex differences in central amygdala reactivity following psychedelic drug exposure","author":"Effinger","year":"2022","journal-title":"bioRxiv"},{"key":"10.1016\/j.neuropharm.2023.109422_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2020.110033","article-title":"Modulation by chronic stress and ketamine of ionotropic AMPA\/NMDA and metabotropic glutamate receptors in the rat hippocampus","volume":"104","author":"Elhussiny","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109422_bib76","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.biopsych.2018.01.027","article-title":"Default mode connectivity in major depressive disorder measured up to 10 days after ketamine administration","volume":"84","author":"Evans","year":"2018","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib77","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1038\/npp.2015.112","article-title":"Rapid antidepressant action and restoration of excitatory synaptic strength after chronic stress by negative modulators of alpha5-containing GABAA receptors","volume":"40","author":"Fischell","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib78","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910706","article-title":"Many drugs of abuse may be acutely transformed to dopamine, norepinephrine and epinephrine in vivo","volume":"22","author":"Fitzgerald","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib79","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41398-018-0239-y","article-title":"Gamma oscillations as a biomarker for major depression: an emerging topic","volume":"8","author":"Fitzgerald","year":"2018","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109422_bib80","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/09540261.2018.1481827","article-title":"Psychedelics as anti-inflammatory agents","volume":"30","author":"Flanagan","year":"2018","journal-title":"Int. Rev. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib81","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/7854_2022_367","article-title":"Psychedelics and anti-inflammatory activity in animal models","volume":"56","author":"Flanagan","year":"2022","journal-title":"Curr. Top Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116790","article-title":"5-HT2 receptor activation alleviates airway inflammation and structural remodeling in a chronic mouse asthma model","volume":"236","author":"Flanagan","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib83","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49987-0","article-title":"Activation of 5-HT 2 receptors reduces inflammation in vascular tissue and cholesterol levels in high-fat diet-fed apolipoprotein E knockout mice","volume":"9","author":"Flanagan","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2023.109422_bib84","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fnins.2020.00043","article-title":"Rethinking therapeutic strategies for anorexia nervosa: insights from psychedelic medicine and animal models","volume":"14","author":"Foldi","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib85","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0304-3940(84)90050-8","article-title":"Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid","volume":"48","author":"Foster","year":"1984","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2023.109422_bib86","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jpsychires.2019.01.010","article-title":"Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression","volume":"110","author":"Freeman","year":"2019","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2023.109422_bib87","doi-asserted-by":"crossref","first-page":"8106","DOI":"10.1073\/pnas.1414728112","article-title":"Optogenetic stimulation of infralimbic PFC reproduces ketamine's rapid and sustained antidepressant actions","volume":"112","author":"Fuchikami","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2023.109422_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173954","article-title":"Dextran sulfate sodium-induced inflammation and colitis in mice are ameliorated by (R)-ketamine, but not (S)-ketamine: a role of TrkB signaling","volume":"897","author":"Fujita","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib89","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1177\/0269881119845793","article-title":"Cessation and reduction in alcohol consumption and misuse after psychedelic use","volume":"33","author":"Garcia-Romeu","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib90","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1172\/JCI130808","article-title":"GABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions","volume":"130","author":"Gerhard","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.neuropharm.2023.109422_bib91","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S0091-3057(02)00844-4","article-title":"Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors","volume":"73","author":"Gewirtz","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"S1","key":"10.1016\/j.neuropharm.2023.109422_bib92","doi-asserted-by":"crossref","first-page":"S334","DOI":"10.1192\/j.eurpsy.2021.897","article-title":"Efficacy and safety of mij821 in patients with treatment-resistant depression: results from a randomized, placebo-controlled, proof-of-concept study","volume":"64","author":"Ghaemi","year":"2021","journal-title":"Eur. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104669","article-title":"Ketamine rapidly reverses stress-induced impairments in GABAergic transmission in the prefrontal cortex in male rodents","volume":"134","author":"Ghosal","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2023.109422_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172856","article-title":"Electrophysiological biomarkers of antidepressant response to ketamine in treatment-resistant depression: gamma power and long-term potentiation","volume":"189","author":"Gilbert","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2023.109422_bib95","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/sj.mp.4001032","article-title":"Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH\/NE states","volume":"7","author":"Gold","year":"2002","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib96","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-16325-w","article-title":"Psilocybin reduces low frequency oscillatory power and neuronal phase-locking in the anterior cingulate cortex of awake rodents","volume":"12","author":"Golden","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2023.109422_bib97","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/7854_2021_298","article-title":"Effects of setting on psychedelic experiences, therapies, and outcomes: a rapid scoping review of the literature","volume":"56","author":"Golden","year":"2022","journal-title":"Curr. Top Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib98","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2023.109422_bib99","series-title":"The Safety and Efficacy of COMP360 Psilocybin Therapy in Treatment-Resistant Depression: Results from a Phase IIb Randomized Controlled Trial","author":"Goodwin","year":"2022"},{"key":"10.1016\/j.neuropharm.2023.109422_bib100","article-title":"Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality","volume":"12","author":"Grant","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2023.109422_bib101","doi-asserted-by":"crossref","first-page":"S322","DOI":"10.1016\/j.biopsych.2021.02.804","article-title":"Acute experiences during infusions cause extra-pharmacological antidepressant effects in ketamine treatment: evidence from randomized, placebo-controlled trials","volume":"89","author":"Greenwald","year":"2021","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib102","article-title":"A qualitative study of patients' experience of ketamine treatment for depression: the \u2018Ketamine and me\u2019 project","volume":"4","author":"Griffiths","year":"2021","journal-title":"J. Affect Disord. Rep."},{"key":"10.1016\/j.neuropharm.2023.109422_bib103","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib104","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.706894","article-title":"Mice lacking GABAA receptor \u03b4 subunit have altered pharmaco-EEG responses to multiple drugs","volume":"12","author":"Grotell","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib106","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3390\/metabo12050459","article-title":"Glutamate efflux across the blood\u2013brain barrier: new perspectives on the relationship between depression and the glutamatergic system","volume":"12","author":"Gruenbaum","year":"2022","journal-title":"Metabolites"},{"key":"10.1016\/j.neuropharm.2023.109422_bib107","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.bbi.2015.06.001","article-title":"Cumulative meta-analysis of interleukins 6 and 1\u03b2, tumour necrosis factor \u03b1 and C-reactive protein in patients with major depressive disorder","volume":"49","author":"Haapakoski","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2023.109422_bib108","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pnpbp.2013.04.009","article-title":"Monoamine neurocircuitry in depression and strategies for new treatments","volume":"45","author":"Hamon","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109422_bib109","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41467-018-08168-9","article-title":"Optogenetic stimulation of medial prefrontal cortex Drd1 neurons produces rapid and long-lasting antidepressant effects","volume":"10","author":"Hare","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2023.109422_bib110","article-title":"Constructing drug effects: a history of set and setting","volume":"3","author":"Hartogsohn","year":"2017","journal-title":"Drug Sci. Pol. Law"},{"key":"10.1016\/j.neuropharm.2023.109422_bib111","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/pcn.12902","article-title":"Rapid\u2010acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective","volume":"73","author":"Hashimoto","year":"2019","journal-title":"Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib112","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","article-title":"Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose\u2013effect study","volume":"172","author":"Hasler","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib113","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00213-008-1129-4","article-title":"Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis","volume":"199","author":"Heekeren","year":"2008","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib114","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S0893-133X(00)00194-9","article-title":"Comparison of the effects of ketamine and memantine on prolactin and cortisol release in men. a randomized, double-blind, placebo-controlled trial","volume":"24","author":"Hergovich","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114892","article-title":"Mechanisms of ketamine and its metabolites as antidepressants","volume":"197","author":"Hess","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib116","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2022489118","article-title":"Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice","volume":"118","author":"Hesselgrave","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"Suppl. 6","key":"10.1016\/j.neuropharm.2023.109422_bib117","first-page":"4","article-title":"History and evolution of the monoamine hypothesis of depression","volume":"61","author":"Hirschfeld","year":"2000","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib118","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41386-022-01297-2","article-title":"Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects","volume":"47","author":"Holze","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib119","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jad.2022.03.047","article-title":"The efficacy and tolerability of memantine for depressive symptoms in major mental diseases: a systematic review and updated meta-analysis of double-blind randomized controlled trials","volume":"306","author":"Hsu","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2023.109422_bib120","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1124\/pharmrev.120.000056","article-title":"Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms","volume":"73","author":"Inserra","year":"2021","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2023.109422_bib121","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/s41380-019-0501-6","article-title":"Persistent depressive symptoms, HPA-axis hyperactivity, and inflammation: the role of cognitive-affective and somatic symptoms","volume":"25","author":"Iob","year":"2020","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib122","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1093\/ijnp\/pyab010","article-title":"Repeated but not single administration of ketamine prolongs increases of the firing activity of norepinephrine and dopamine neurons","volume":"24","author":"Iro","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib123","article-title":"Nitrous oxide, a rapid antidepressant, has ketamine-like effects on excitatory transmission in adult hippocampus","volume":"22","author":"Izumi","year":"2022","journal-title":"Biol Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib124","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.biopsych.2018.02.006","article-title":"The gamma-aminobutyric acid B receptor in depression and reward","volume":"83","author":"Jacobson","year":"2018","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib125","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fncel.2018.00314","article-title":"Sigma-1 receptor-modulated neuroinflammation in neurological diseases","volume":"12","author":"Jia","year":"2018","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib126","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib127","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","article-title":"Classic psychedelics: an integrative review of epidemiology, therapeutics, mystical experience, and brain network function","volume":"197","author":"Johnson","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2023.109422_bib128","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib129","unstructured":"Johnston, J. N., Greenwald, M., Henter, I. D., Kraus, C., Mkrtchian, A., Clark, N. G., Park, L. T., Gold, P., Zarate, C. A. J., Kadriu, B., submitted. Inflammation, stress, and depression: an exploration of ketamine's therapeutic profile. Drug Discov. Today."},{"key":"10.1016\/j.neuropharm.2023.109422_bib130","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1038\/s41598-022-06580-2","article-title":"Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study","volume":"12","author":"Jones","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2023.109422_bib131","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19ac13138","article-title":"Not so fast: recent successes and failures in treating depression","volume":"81","author":"Kadriu","year":"2020","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib132","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/ijnp\/pyaa087","article-title":"Ketamine and serotonergic psychedelics: common mechanisms underlying the effects of rapid-acting antidepressants","volume":"24","author":"Kadriu","year":"2021","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib133","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/ijnp\/pyy094","article-title":"Glutamatergic neurotransmission: pathway to developing novel rapid-acting antidepressant treatments","volume":"22","author":"Kadriu","year":"2019","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2019.172827","article-title":"Rapastinel, a novel glutamatergic agent with ketamine-like antidepressant actions: convergent mechanisms","volume":"188","author":"Kato","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2023.109422_bib135","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1021\/acschemneuro.1c00660","article-title":"Pharmahuasca and DMT rescue ROS production and differentially expressed genes observed after predator and psychosocial stress: relevance to human PTSD","volume":"13","author":"Kelley","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib136","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/bja\/aev135","article-title":"Effect of subanaesthetic ketamine on plasma and saliva cortisol secretion","volume":"115","author":"Khalili-Mahani","year":"2015","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.neuropharm.2023.109422_bib137","doi-asserted-by":"crossref","first-page":"27028","DOI":"10.1073\/pnas.1911446116","article-title":"5-HT2A receptor activation normalizes stress-induced dysregulation of GABAergic signaling in the ventral tegmental area","volume":"116","author":"Kimmey","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2023.109422_bib138","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1017\/S0033291716000064","article-title":"Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories","volume":"46","author":"Kishimoto","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2023.109422_bib139","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1073\/pnas.1916570117","article-title":"Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents","volume":"117","author":"Klein","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2023.109422_bib140","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0091-3057(02)00845-6","article-title":"Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice","volume":"73","author":"K\u0142odzinska","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2023.109422_bib141","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41386-022-01361-x","article-title":"Sustained effects of single doses of classical psychedelics in humans","volume":"48","author":"Knudsen","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib142","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.euroneuro.2021.09.006","article-title":"Depression and inflammation: correlation between changes in inflammatory markers with antidepressant response and long-term prognosis","volume":"54","author":"Kofod","year":"2022","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2023.109422_bib143","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/acps.12698","article-title":"Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies","volume":"135","author":"K\u00f6hler","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.neuropharm.2023.109422_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2020.112548","article-title":"Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant","volume":"384","author":"Kokane","year":"2020","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109422_bib145","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.pharep.2019.05.022","article-title":"An immune gate of depression \u2013 early neuroimmune development in the formation of the underlying depressive disorder","volume":"71","author":"Kowalczyk","year":"2019","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.neuropharm.2023.109422_bib146","article-title":"The DMT and psilocin treatment changes CD11b+ activated microglia immunological phenotype","author":"Koz\u0142owska","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.neuropharm.2023.109422_bib147","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/s41386-020-0624-0","article-title":"Evaluating global brain connectivity as an imaging marker for depression: influence of preprocessing strategies and placebo-controlled ketamine treatment","volume":"45","author":"Kraus","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib148","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/13651501.2016.1254802","article-title":"Administration of ketamine for unipolar and bipolar depression","volume":"21","author":"Kraus","year":"2017","journal-title":"Int. J. Psychiatr. Clin. Pract."},{"key":"10.1016\/j.neuropharm.2023.109422_bib149","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s41398-021-01268-z","article-title":"Depression treatment response to ketamine: sex-specific role of interleukin-8, but not other inflammatory markers","volume":"11","author":"Kruse","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109422_bib150","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.pnpbp.2010.08.026","article-title":"In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression","volume":"35","author":"Kubera","year":"2011","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109422_bib151","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1089\/zeb.2016.1251","article-title":"Exploring hallucinogen pharmacology and psychedelic medicine with zebrafish models","volume":"13","author":"Kyzar","year":"2016","journal-title":"Zebrafish"},{"key":"10.1016\/j.neuropharm.2023.109422_bib152","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0893-133X(94)00131-I","article-title":"Subanesthetic doses of ketamine stimulate psychosis in schizophrenia","volume":"13","author":"Lahti","year":"1995","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib153","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1038\/tp.2014.105","article-title":"Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression","volume":"4","author":"Lally","year":"2014","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109422_bib154","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4088\/JCP.v66n0114","article-title":"Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine","volume":"66","author":"Landen","year":"2005","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2021.120094","article-title":"Looking beyond the opioid receptor: a desperate need for new treatments for opioid use disorder","volume":"432","author":"Lee","year":"2022","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib156","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2023.109422_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.ntt.2022.107079","article-title":"Ketamine enhances dopamine D1 receptor expression by modulating microRNAs in a ketamine-induced schizophrenia-like mouse model","volume":"91","author":"Li","year":"2022","journal-title":"Neurotoxicol. Teratol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.ynstr.2022.100503","article-title":"(2R, 6R)-hydroxynorketamine acts through GluA1-induced synaptic plasticity to alleviate PTSD-like effects in rat models","volume":"21","author":"Li","year":"2022","journal-title":"Neurobiol Stress"},{"key":"10.1016\/j.neuropharm.2023.109422_bib159","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3389\/fncel.2017.00305","article-title":"From serotonin to neuroplasticity: evolvement of theories for major depressive disorder","volume":"11","author":"Liu","year":"2017","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib160","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.brainresbull.2016.05.016","article-title":"Ketamine abuse potential and use disorder","volume":"126","author":"Liu","year":"2016","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2023.109422_bib161","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1111\/bph.13222","article-title":"Ketamine and phencyclidine: the good, the bad and the unexpected","volume":"172","author":"Lodge","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib162","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1021\/acschemneuro.9b00288","article-title":"Role of serotonin and noradrenaline in the rapid antidepressant action of ketamine","volume":"10","author":"L\u00f3pez-Gil","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib163","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/7854_2017_478","article-title":"Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways","volume":"36","author":"L\u00f3pez-Gim\u00e9nez","year":"2018","journal-title":"Curr. Top Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib164","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/104024","article-title":"Quinolinic acid: an endogenous neurotoxin with multiple targets","author":"Lugo-Huitr\u00f3n","year":"2013","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.neuropharm.2023.109422_bib165","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1073\/pnas.1816071116","article-title":"Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function","volume":"116","author":"Lumsden","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2023.109422_bib166","doi-asserted-by":"crossref","first-page":"F1000","DOI":"10.12688\/f1000research.18758.1","article-title":"Brexanolone, a neurosteroid antidepressant, vindicates the GABAergic deficit hypothesis of depression and may foster resilience","volume":"8","author":"L\u00fcscher","year":"2019","journal-title":"F1000Res"},{"key":"10.1016\/j.neuropharm.2023.109422_bib167","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2023.109422_bib168","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1021\/acsptsci.0c00065","article-title":"Transient stimulation with psychoplastogens is sufficient to initiate neuronal growth","volume":"4","author":"Ly","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib169","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1152\/jn.1987.58.2.251","article-title":"Use-dependent block of excitatory amino acid currents in cultured neurons by ketamine","volume":"58","author":"MacDonald","year":"1987","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112845","article-title":"Metabolomics and integrated network analysis reveal roles of endocannabinoids and large neutral amino acid balance in the ayahuasca experience","volume":"149","author":"Madrid-Gambin","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.neuropharm.2023.109422_bib171","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/14728214.2021.1898588","article-title":"Efficacy of dextromethorphan for the treatment of depression: a systematic review of preclinical and clinical trials","volume":"26","author":"Majeed","year":"2021","journal-title":"Expet Opin. Emerg. Drugs"},{"key":"10.1016\/j.neuropharm.2023.109422_bib172","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00213-021-05876-x","article-title":"Serotonin toxicity of serotonergic psychedelics","volume":"239","author":"Malcolm","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2023.109422_bib173","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.647909","article-title":"Sustained, multifaceted improvements in mental well-being following psychedelic experiences in a prospective opportunity sample","volume":"12","author":"Mans","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib174","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jad.2020.09.007","article-title":"A systematic review and meta-analysis of the efficacy of intravenous ketamine infusion for treatment resistant depression: January 2009\u2013January 2019","volume":"277","author":"Marcantoni","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2023.109422_bib175","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11065-012-9199-9","article-title":"The default mode network and recurrent depression: a neurobiological model of cognitive risk factors","volume":"22","author":"Marchetti","year":"2012","journal-title":"Neuropsychol. Rev."},{"key":"10.1016\/j.neuropharm.2023.109422_bib176","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/02698811211050556","article-title":"Psilocybin microdosing does not affect emotion-related symptoms and processing: a preregistered field and lab-based study","volume":"36","author":"Marschall","year":"2022","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib177","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/brainsci8030047","article-title":"Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives","volume":"8","author":"Martinotti","year":"2018","journal-title":"Brain Sci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib178","doi-asserted-by":"crossref","DOI":"10.1038\/s41386-020-0718-8","article-title":"Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin","author":"Mason","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib179","doi-asserted-by":"crossref","DOI":"10.1177\/2045125320916657","article-title":"Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers","volume":"10","author":"Matveychuk","year":"2020","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib180","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.biopsych.2009.11.001","article-title":"Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment","volume":"67","author":"McCabe","year":"2010","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib181","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41573-022-00421-7","article-title":"The promises and perils of psychedelic pharmacology for psychiatry","volume":"21","author":"McClure-Begley","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2023.109422_bib182","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.841648","article-title":"Psilocybin-induced mystical-type experiences are related to persisting positive effects: a quantitative and qualitative report","volume":"13","author":"McCulloch","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib183","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1017\/S0033291714001603","article-title":"A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes","volume":"45","author":"McGirr","year":"2015","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2023.109422_bib184","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jad.2020.06.050","article-title":"The effect of intravenous, intranasal, and oral ketamine in mood disorders: a meta-analysis","volume":"276","author":"McIntyre","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2023.109422_bib185","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jaac.2012.01.011","article-title":"Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression","volume":"51","author":"McMakin","year":"2012","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109422_bib186","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/S2215-0366(20)30255-8","article-title":"Neuroinflammation in psychiatric disorders: PET imaging and promising new targets","volume":"7","author":"Meyer","year":"2020","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib187","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1038\/npp.2013.140","article-title":"Conceptual confluence: the kynurenine pathway as a common target for ketamine and the convergence of the inflammation and glutamate hypotheses of depression","volume":"38","author":"Miller","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib188","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.neuropharm.2015.07.028","article-title":"Two cellular hypotheses explaining the initiation of ketamine's antidepressant actions: direct inhibition and disinhibition","volume":"100","author":"Miller","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib189","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13041-020-00713-2","article-title":"Global knockdown of glutamate decarboxylase 67 elicits emotional abnormality in mice","volume":"14","author":"Miyata","year":"2021","journal-title":"Mol. Brain"},{"key":"10.1016\/j.neuropharm.2023.109422_bib190","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1038\/s41380-020-00878-1","article-title":"Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals","volume":"26","author":"Mkrtchian","year":"2021","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib191","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1007\/s00213-018-4992-7","article-title":"Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects","volume":"235","author":"Moaddel","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2023.109422_bib192","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib193","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.4088\/JCP.v67n1110","article-title":"Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder","volume":"67","author":"Moreno","year":"2006","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib194","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1348\/014466508X396549","article-title":"Does emotion predict the course of major depressive disorder? A review of prospective studies","volume":"48","author":"Morris","year":"2009","journal-title":"Br. J. Clin. Psychol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib195","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s00213-021-05991-9","article-title":"Low doses of LSD reduce broadband oscillatory power and modulate event-related potentials in healthy adults","volume":"239","author":"Murray","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib196","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/17460441.2020.1822814","article-title":"Targeting metabotropic glutamate receptors for rapid-acting antidepressant drug discovery","volume":"16","author":"Musazzi","year":"2021","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.neuropharm.2023.109422_bib197","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","article-title":"Blinding and expectancy confounds in psychedelic randomized controlled trials","volume":"14","author":"Muthukumaraswamy","year":"2021","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib198","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jad.2019.07.076","article-title":"Classical psychedelics for the treatment of depression and anxiety: a systematic review","volume":"258","author":"Muttoni","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2023.109422_bib199","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41398-022-01930-0","article-title":"5-HT2A receptor dysregulation in a schizophrenia relevant mouse model of NMDA receptor hypofunction","volume":"12","author":"Nakao","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109422_bib200","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2020.113245","article-title":"N, N-dimethyltryptamine reduces infarct size and improves functional recovery following transient focal brain ischemia in rats","volume":"327","author":"Nardai","year":"2020","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib201","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075426","article-title":"Serotonin 5-HT2A receptor activation blocks TNF-alpha mediated inflammation in vivo","volume":"8","author":"Nau","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2023.109422_bib202","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00213-021-05767-1","article-title":"Ketamine-induced urological toxicity: potential mechanisms and translation for adults with mood disorders receiving ketamine treatment","volume":"238","author":"Ng","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2023.109422_bib203","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2023.109422_bib204","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cpt.557","article-title":"Psychedelics as medicines: an emerging new paradigm","volume":"101","author":"Nichols","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2023.109422_bib205","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4088\/JCP.v60n0403","article-title":"Residual symptoms in depressed patients who respond acutely to fluoxetine","volume":"60","author":"Nierenberg","year":"1999","journal-title":"J. Clin. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib206","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.2147\/JIR.S317182","article-title":"Anti-inflammatory effects of four psilocybin-containing magic mushroom water extracts in vitro on 15-lipoxygenase activity and on lipopolysaccharide-induced cyclooxygenase-2 and inflammatory cytokines in human U937 macrophage cells","volume":"14","author":"Nkadimeng","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.neuropharm.2023.109422_bib207","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1007\/s00213-022-06105-9","article-title":"The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits","volume":"239","author":"Nogo","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2023.109422_bib208","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/00952990.2017.1310218","article-title":"Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study","volume":"44","author":"Noller","year":"2018","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.neuropharm.2023.109422_bib209","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1523\/JNEUROSCI.4998-12.2013","article-title":"Acute suppression of spontaneous neurotransmission drives synaptic potentiation","volume":"33","author":"Nosyreva","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib210","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1038\/s41380-018-0028-2","article-title":"Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects","volume":"24","author":"Nugent","year":"2019","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib211","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.pscychresns.2018.09.001","article-title":"Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: a replication study","volume":"283","author":"Nugent","year":"2019","journal-title":"Psychiatry Res. Neuroimaging."},{"key":"10.1016\/j.neuropharm.2023.109422_bib212","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1021\/acsptsci.0c00192","article-title":"The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects","volume":"4","author":"Olson","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib213","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2022.114148","article-title":"Nootropic effects of LSD: behavioral, molecular and computational evidence","volume":"356","author":"Ornelas","year":"2022","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib214","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1017\/S0033291718001356","article-title":"Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial","volume":"49","author":"Palhano-Fontes","year":"2019","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2023.109422_bib215","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2020.110239","article-title":"The group II mGlu receptor antagonist LY341495 induces a rapid antidepressant-like effect and enhances the effect of ketamine in the chronic unpredictable mild stress model of depression in C57BL\/6J mice","volume":"109","author":"Pa\u0142ucha-Poniewiera","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109422_bib216","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/1355621021000005937","article-title":"The pharmacology of psilocybin","volume":"7","author":"Passie","year":"2002","journal-title":"Addiction Biol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib217","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41380-018-0117-2","article-title":"Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches","volume":"24","author":"Peci\u00f1a","year":"2019","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib218","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/s41386-022-01324-2","article-title":"Effects of a psychedelic 5-HT2A receptor agonist on anxiety-related behavior and fear processing in mice","volume":"47","author":"P\u0119dzich","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib332","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1124\/mi.9.6.5","article-title":"Wishing away inflammation? New links between serotonin and TNF signaling","volume":"9","author":"Pelletier","year":"2009","journal-title":"Mol. Intervent."},{"key":"10.1016\/j.neuropharm.2023.109422_bib219","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s40262-016-0383-6","article-title":"Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy","volume":"55","author":"Peltoniemi","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.neuropharm.2023.109422_bib220","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1080\/17460441.2020.1781812","article-title":"What ketamine can teach us about the opioid system in depression","volume":"15","author":"Perez-Caballero","year":"2020","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.neuropharm.2023.109422_bib221","doi-asserted-by":"crossref","first-page":"514","DOI":"10.2174\/1570159X13666150515234920","article-title":"The emerging role of metabotropic glutamate receptors in the pathophysiology of chronic stress-related disorders","volume":"14","author":"Peterlik","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib222","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172913","article-title":"Cortical and raphe GABAA, AMPA receptors and glial GLT-1 glutamate transporter contribute to the sustained antidepressant activity of ketamine","volume":"192","author":"Pham","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2023.109422_bib223","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/17460441.2022.2111415","article-title":"Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2\/3 receptor antagonism","volume":"17","author":"Pilc","year":"2022","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.neuropharm.2023.109422_bib224","article-title":"Allopregnanolone in postpartum depression","volume":"3","author":"Pinna","year":"2022","journal-title":"Front Global Womens Health"},{"key":"10.1016\/j.neuropharm.2023.109422_bib225","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1007\/s12035-021-02352-7","article-title":"Metaplastic effects of ketamine and MK-801 on glutamate receptors expression in rat medial prefrontal cortex and hippocampus","volume":"58","author":"Piva","year":"2021","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib226","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1080\/14737175.2019.1643237","article-title":"An update on NMDA antagonists in depression","volume":"19","author":"Pochwat","year":"2019","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neuropharm.2023.109422_bib227","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/ijnp\/pyab082","article-title":"Sex differences in the behavioral, molecular, and structural effects of ketamine treatment in depression","volume":"25","author":"Ponton","year":"2022","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib228","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1038\/s41380-020-0796-3","article-title":"Cell-type specific modulation of NMDA receptors triggers antidepressant actions","volume":"26","author":"Pothula","year":"2021","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib229","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1192\/bjp.bp.108.051110","article-title":"Emotional side-effects of selective serotonin reuptake inhibitors: qualitative study","volume":"195","author":"Price","year":"2009","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109422_bib230","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41380-019-0615-x","article-title":"Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model","volume":"25","author":"Price","year":"2020","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib231","article-title":"Rapid antidepressant-like effect of non-hallucinogenic psychedelic analog lisuride, but not hallucinogenic psychedelic DOI, in lipopolysaccharide-treated mice","volume":"222","author":"Qu","year":"2022","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2023.109422_bib232","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3390\/ph15020125","article-title":"Combined administration of (R)-ketamine and the mGlu2\/3 receptor antagonist LY341495 induces rapid and sustained effects in the CUMS model of depression via a TrkB\/BDNF-dependent mechanism","volume":"15","author":"Rafa\u0142o-Uli\u0144ska","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.neuropharm.2023.109422_bib233","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113633","article-title":"The effectiveness of (R)-ketamine and its mechanism of action differ from those of (S)-ketamine in a chronic unpredictable mild stress model of depression in C57BL\/6J mice","volume":"418","author":"Rafa\u0142o-Uli\u0144ska","year":"2022","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109422_bib234","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.831092","article-title":"Effects of naturalistic psychedelic use on depression, anxiety, and well-being: associations with patterns of use, reported harms, and transformative mental states","volume":"13","author":"Raison","year":"2022","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib235","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","article-title":"Psychedelics and psychedelic-assisted psychotherapy","volume":"177","author":"Reiff","year":"2020","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib236","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.biopsych.2016.02.009","article-title":"Bidirectional homeostatic regulation of a depression-related brain state by GABAergic deficits and ketamine treatment","volume":"80","author":"Ren","year":"2016","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib237","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.neuropharm.2015.08.034","article-title":"Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2, 5-dimethoxy-substituted phenethylamines (2C drugs)","volume":"99","author":"Rickli","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib238","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpr.2021.101978","article-title":"Association of opioid misuse with anxiety and depression: a systematic review of the literature","volume":"84","author":"Rogers","year":"2021","journal-title":"Clin. Psychol. Rev."},{"key":"10.1016\/j.neuropharm.2023.109422_bib239","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/307106","article-title":"Pharmacology of hallucinations: several mechanisms for one single symptom","volume":"2014","author":"Rolland","year":"2014","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.neuropharm.2023.109422_bib240","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jpsychires.2021.03.002","article-title":"Clinical and biological predictors of psychedelic response in the treatment of psychiatric and addictive disorders: a systematic review","volume":"137","author":"Romeo","year":"2021","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2023.109422_bib241","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1177\/0269881120919957","article-title":"Efficacy of psychedelic treatments on depressive symptoms: a meta-analysis","volume":"34","author":"Romeo","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib242","article-title":"Psilocybin microdosers demonstrate greater observed improvements in mood and mental health at one month relative to non-microdosing controls","volume":"12","author":"Rootman","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2023.109422_bib243","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.pharep.2016.05.010","article-title":"Antidepressant-like effects of ascorbic acid and ketamine involve modulation of GABAA and GABAB receptors","volume":"68","author":"Rosa","year":"2016","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.neuropharm.2023.109422_bib244","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/j.clinph.2015.10.062","article-title":"The effects of ketamine on the mismatch negativity (MMN) in humans \u2013 a meta-analysis","volume":"127","author":"Rosburg","year":"2016","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib245","first-page":"140","article-title":"Selective prefrontal disinhibition in a roving auditory oddball paradigm under N-methyl-D-aspartate receptor blockade","volume":"4","author":"Rosch","year":"2019","journal-title":"Biol. Psychiatr. Cogn. Neurosci. Neuroimag."},{"key":"10.1016\/j.neuropharm.2023.109422_bib246","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fphar.2017.00974","article-title":"Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression","volume":"8","author":"Roseman","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib247","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib248","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","article-title":"Psychiatry & the psychedelic drugs. Past, present & future","volume":"142","author":"Rucker","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib249","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/s41386-021-01221-0","article-title":"(2-Aminopropyl) benzo [\u03b2] thiophenes (APBTs) are novel monoamine transporter ligands that lack stimulant effects but display psychedelic-like activity in mice","volume":"47","author":"Rudin","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib250","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib251","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/jnc.15544","article-title":"Psychedelic\u2010inspired approaches for treating neurodegenerative disorders","volume":"162","author":"Saeger","year":"2022","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2023.109422_bib252","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/ijnp\/pyx036","article-title":"Assessing the psychedelic \u201cafter-glow\u201d in ayahuasca users: post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities","volume":"20","author":"Sampedro","year":"2017","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib253","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","article-title":"Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a SPECT study","volume":"36","author":"Sanches","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib254","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/da.22536","article-title":"A review of ketamine abuse and diversion","volume":"33","author":"Sassano-Higgins","year":"2016","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.neuropharm.2023.109422_bib255","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1176\/appi.ajp.2020.20030272","article-title":"Some comments on psychedelic research","volume":"177","author":"Schatzberg","year":"2020","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib256","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/luts.12355","article-title":"Is medicinal ketamine associated with urinary dysfunction issues? Assessment of both the European Medicines Agency (EMA) and the UK Yellow Card Scheme pharmacovigilance database\u2010related reports","volume":"13","author":"Schifano","year":"2021","journal-title":"Low. Urin. Tract. Symptoms"},{"key":"10.1016\/j.neuropharm.2023.109422_bib257","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/npp.2011.261","article-title":"Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments","volume":"37","author":"Schmidt","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib258","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00213-012-2811-0","article-title":"The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions","volume":"225","author":"Schmidt","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib259","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fnbeh.2018.00070","article-title":"Effects of subanesthetic ketamine administration on visual and auditory event-related potentials (ERP) in humans: a systematic review","volume":"12","author":"Schwertner","year":"2018","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib260","doi-asserted-by":"crossref","first-page":"11020","DOI":"10.1073\/pnas.1000446107","article-title":"Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus","volume":"107","author":"Sheline","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2023.109422_bib261","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.549903","article-title":"Effect of ketamine on limbic GABA and glutamate: a human in vivo multivoxel magnetic resonance spectroscopy study","volume":"11","author":"Silberbauer","year":"2020","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib262","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/s41586-022-04993-7","article-title":"Dual action of ketamine confines addiction liability","volume":"608","author":"Simmler","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2023.109422_bib263","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1161\/HYPERTENSIONAHA.120.16715","article-title":"Association between lifetime classic psychedelic use and hypertension in the past year","volume":"77","author":"Simonsson","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.neuropharm.2023.109422_bib264","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-021-93787-4","article-title":"Associations between lifetime classic psychedelic use and cardiometabolic diseases","volume":"11","author":"Simonsson","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2023.109422_bib265","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1177\/0269881121996863","article-title":"Associations between lifetime classic psychedelic use and markers of physical health","volume":"35","author":"Simonsson","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib266","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/jnc.15540","article-title":"Molecular insights into psychedelic drug action","volume":"162","author":"Slocum","year":"2022","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2023.109422_bib267","article-title":"Psilocybin combines rapid synaptogenic and anti-inflammatory effects in vitro","author":"Smedfors","year":"2022","journal-title":"Res. Square"},{"key":"10.1016\/j.neuropharm.2023.109422_bib268","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/ijnp\/pyx085","article-title":"Assessment of ketamine binding of the serotonin transporter in humans with positron emission tomography","volume":"21","author":"Spies","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib269","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.735523","article-title":"Study protocol for \u201cpsilocybin as a treatment for anorexia nervosa: a pilot study\u201d","volume":"12","author":"Spriggs","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib270","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/PSY.0b013e31820ad12b","article-title":"Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research","volume":"73","author":"Stetler","year":"2011","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.neuropharm.2023.109422_bib271","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archpsyc.1994.03950020009001","article-title":"Dose-response study of N, N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects","volume":"51","author":"Strassman","year":"1994","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib272","first-page":"45","article-title":"Ketamine enhances visual sensory evoked potential long-term potentiation in patients with major depressive disorder","volume":"5","author":"Sumner","year":"2020","journal-title":"Biol. Psychiatr. Cogn. Neurosci. Neuroimag."},{"key":"10.1016\/j.neuropharm.2023.109422_bib273","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.euroneuro.2020.07.009","article-title":"Ketamine improves short-term plasticity in depression by enhancing sensitivity to prediction errors","volume":"38","author":"Sumner","year":"2020","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2023.109422_bib274","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.3390\/ijms22041640","article-title":"Inflammatory depression\u2014mechanisms and non-pharmacological intervention","volume":"22","author":"Suneson","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib275","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41398-020-0844-4","article-title":"A randomized placebo-controlled PET study of ketamine' s effect on serotonin1B receptor binding in patients with SSRI-resistant depression","volume":"10","author":"Tiger","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109422_bib276","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib277","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.665739","article-title":"Microglia function on precursor cells in the adult hippocampus and their responsiveness to serotonin signaling","volume":"9","author":"Turkin","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib279","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1017\/S0033291711001905","article-title":"Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms","volume":"42","author":"Uher","year":"2012","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2023.109422_bib280","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/sj.npp.1300005","article-title":"Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia","volume":"28","author":"Umbricht","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib281","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1556\/2054.2021.00152","article-title":"A narrative review of the pharmacological, cultural and psychological literature on ibogaine","volume":"5","author":"Underwood","year":"2021","journal-title":"J. Psychedelic Stud."},{"key":"10.1016\/j.neuropharm.2023.109422_bib282","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jad.2013.06.004","article-title":"CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies","volume":"150","author":"Valkanova","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2023.109422_bib283","first-page":"735","article-title":"Effects of serial ketamine infusions on corticolimbic functional connectivity in major depression","volume":"6","author":"Vasavada","year":"2021","journal-title":"Biol. Psychiatr. Cogn. Neurosci. Neuroimag."},{"key":"10.1016\/j.neuropharm.2023.109422_bib284","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s00213-021-05913-9","article-title":"Sex-specific effects of psychedelics on prepulse inhibition of startle in 129S6\/SvEv mice","volume":"239","author":"Vohra","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2023.109422_bib285","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","article-title":"Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders","volume":"21","author":"Vollenweider","year":"2020","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib286","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/a-1721-2914","article-title":"Classic psychedelic drugs: update on biological mechanisms","volume":"55","author":"Vollenweider","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.neuropharm.2023.109422_bib287","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/npp.2013.71","article-title":"NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL\/6J mice","volume":"38","author":"Walker","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib288","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/schbul\/sbx035","article-title":"Meta-analysis of cerebrospinal fluid cytokine and tryptophan catabolite alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder, and depression","volume":"44","author":"Wang","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.neuropharm.2023.109422_bib289","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1097\/ALN.0000000000001483","article-title":"Ketamine increases the function of \u03b3-aminobutyric acid type A receptors in hippocampal and cortical neurons","volume":"126","author":"Wang","year":"2017","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib290","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/03009734.2015.1060281","article-title":"The rapid antidepressant effect of ketamine in rats is associated with down-regulation of pro-inflammatory cytokines in the hippocampus","volume":"120","author":"Wang","year":"2015","journal-title":"Ups. J. Med. Sci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib291","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.bbr.2019.01.057","article-title":"Ketamine improved depressive-like behaviors via hippocampal glucocorticoid receptor in chronic stress induced- susceptible mice","volume":"364","author":"Wang","year":"2019","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2023.109422_bib292","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1021\/acschemneuro.8b00294","article-title":"DARK classics in chemical neuroscience: ibogaine","volume":"9","author":"Wasko","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib293","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1111\/ejn.13807","article-title":"Temporal coupling of field potentials and action potentials in the neocortex","volume":"48","author":"Watson","year":"2018","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib294","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41380-021-01121-1","article-title":"Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor","volume":"27","author":"Wei","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib295","doi-asserted-by":"crossref","DOI":"10.1177\/20451253211056743","article-title":"Systematic review and meta-analysis of randomized controlled trials of ketamine in the treatment of refractory anxiety spectrum disorders","volume":"11","author":"Whittaker","year":"2021","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib296","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.mp.4001600","article-title":"Ido and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity","volume":"10","author":"Wichers","year":"2005","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib297","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis","volume":"175","author":"Wilkinson","year":"2018","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib298","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s41380-019-0503-4","article-title":"Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism","volume":"24","author":"Williams","year":"2019","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib299","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","article-title":"Attenuation of antidepressant effects of ketamine by opioid receptor antagonism","volume":"175","author":"Williams","year":"2018","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib300","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.neubiorev.2021.05.006","article-title":"Therapeutic potential of ketamine for alcohol use disorder","volume":"126","author":"Worrell","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2023.109422_bib301","doi-asserted-by":"crossref","first-page":"6713","DOI":"10.3390\/ijms23126713","article-title":"Effect of psilocybin and ketamine on brain neurotransmitters, glutamate receptors, DNA and rat behavior","volume":"23","author":"Wotjas","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib302","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/s41380-018-0083-8","article-title":"NMDAR-independent, cAMP-dependent antidepressant actions of ketamine","volume":"24","author":"Wray","year":"2019","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib303","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.biopsych.2020.12.022","article-title":"Ketamine rapidly enhances glutamate-evoked dendritic spinogenesis in medial prefrontal cortex through dopaminergic mechanisms","volume":"89","author":"Wu","year":"2021","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib304","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.64041","article-title":"Attenuated dopamine signaling after aversive learning is restored by ketamine to rescue escape actions","volume":"10","author":"Wu","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.neuropharm.2023.109422_bib305","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s00213-022-06118-4","article-title":"Mediation of the behavioral effects of ketamine and (2R, 6R)-hydroxynorketamine in mice by kappa opioid receptors","volume":"239","author":"Wulf","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2023.109422_bib306","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1038\/tp.2013.112","article-title":"A possible mechanism of the nucleus accumbens and ventral pallidum 5-HT1B receptors underlying the antidepressant action of ketamine: a PET study with macaques","volume":"4","author":"Yamanaka","year":"2014","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109422_bib307","doi-asserted-by":"crossref","first-page":"pyw080","DOI":"10.1093\/ijnp\/pyw080","article-title":"Antidepressant effects of (+)-MK-801 and (-)-MK-801 in the social defeat stress model","volume":"19","author":"Yang","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib308","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12888-018-1845-1","article-title":"N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trial","volume":"18","author":"Yang","year":"2018","journal-title":"BMC Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib309","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.biopsych.2017.05.016","article-title":"Mechanistic target of rapamycin\u2013independent antidepressant effects of (R)-ketamine in a social defeat stress model","volume":"83","author":"Yang","year":"2018","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib310","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41398-019-0624-1","article-title":"Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites","volume":"9","author":"Yang","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2023.109422_bib311","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1038\/mp.2017.239","article-title":"Ketamine and its metabolite (2R, 6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit","volume":"23","author":"Yao","year":"2018","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib312","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/s41380-021-01377-7","article-title":"Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine","volume":"27","author":"Yao","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib313","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1124\/jpet.108.143461","article-title":"Serotonin 5-hydroxytryptamine2A receptor activation suppresses tumor necrosis factor-\u03b1-induced inflammation with extraordinary potency","volume":"327","author":"Yu","year":"2008","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2023.109422_bib314","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fnint.2018.00054","article-title":"The varieties of the psychedelic experience: a preliminary study of the association between the reported subjective effects and the binding affinity profiles of substituted phenethylamines and tryptamines","volume":"12","author":"Zamberlan","year":"2018","journal-title":"Front. Integr. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib315","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/mp.2017.255","article-title":"Mechanisms of ketamine action as an antidepressant","volume":"23","author":"Zanos","year":"2018","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib316","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1073\/pnas.1819540116","article-title":"(2R,6R)-hydroxynorketamine exerts mGlu2 receptor-dependent antidepressant actions","volume":"116","author":"Zanos","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2023.109422_bib317","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2023.109422_bib318","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms","volume":"70","author":"Zanos","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2023.109422_bib319","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40263-018-0492-x","article-title":"Convergent mechanisms underlying rapid antidepressant action","volume":"32","author":"Zanos","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2023.109422_bib320","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.biopsych.2011.12.010","article-title":"Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial","volume":"71","author":"Zarate","year":"2012","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib321","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib322","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2021.173228","article-title":"Opioid receptor system contributes to the acute and sustained antidepressant-like effects, but not the hyperactivity motor effects of ketamine in mice","volume":"208","author":"Zhang","year":"2021","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2023.109422_bib323","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s00213-021-05889-6","article-title":"(R)-Ketamine attenuates LPS-induced endotoxin-derived delirium through inhibition of neuroinflammation","volume":"238","author":"Zhang","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib324","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109219","article-title":"Arketamine, a new rapid-acting antidepressant: a historical review and future directions","volume":"218","author":"Zhang","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2023.109422_bib325","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/ijnp\/pyx100","article-title":"5-Hydroxytryptamine-independent antidepressant actions of (R)-ketamine in a chronic social defeat stress model","volume":"21","author":"Zhang","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib326","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.biopsych.2018.11.006","article-title":"Lack of opioid system in the antidepressant actions of ketamine","volume":"85","author":"Zhang","year":"2019","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib327","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41586-021-03769-9","article-title":"Structural basis of ketamine action on human NMDA receptors","volume":"596","author":"Zhang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2023.109422_bib328","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1021\/acschemneuro.9b00669","article-title":"Low-dose ketamine improves LPS-induced depression-like behavior in rats by activating cholinergic anti-inflammatory pathways","volume":"11","author":"Zhao","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2023.109422_bib329","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1365-2125.2012.04198.x","article-title":"Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression","volume":"74","author":"Zhao","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2023.109422_bib330","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.eurpsy.2013.10.005","article-title":"Ketamine-induced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex","volume":"29","author":"Zhou","year":"2014","journal-title":"Eur. Psychiatr."},{"key":"10.1016\/j.neuropharm.2023.109422_bib331","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bbi.2018.09.007","article-title":"Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression","volume":"74","author":"Zhou","year":"2018","journal-title":"Brain Behav. Immun."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823000126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390823000126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:24:53Z","timestamp":1758439493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390823000126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":329,"alternative-id":["S0028390823000126"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109422","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2023.109422","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109422"}}